安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics is a biotechnology company offering a new approach on drug development in Duchenne muscular dystrophy and beyond We are patient-focused first, while advancing precision medicine
- Investors :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc (NASDAQ: CAPR) is a biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases
- Our Science :: Capricor Therapeutics, Inc. (CAPR)
Ongoing research at Capricor spans the areas of product development and characterization of potential expanded use of deramiocel
- About Us :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics is a publicly traded (NASDAQ: CAPR) biotechnology company with a mission to develop groundbreaking therapies that make a meaningful impact on patients’ lives Capricor is focused on the development of biologics, primarily cell and exosome-based technologies to treat or prevent a broad range of diseases
- Capricor Therapeutics Announces Intent to File Biologics License . . .
Capricor Therapeutics, Inc (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases At the forefront of our innovation is our lead product candidate, deramiocel (CAP-1002), an allogeneic cardiac-derived cell therapy
- Capricor Therapeutics Announces Orphan Drug Designation for Becker . . .
U S FDA grants Orphan Drug Designation to Deramiocel for the treatment of Becker Muscular Dystrophy, broadening Capricor’s focus in neuromuscular diseases; Capricor remains on track for the August 31, 2025, PDUFA date for Deramiocel in Duchenne Muscular Dystrophy following successful FDA Pre-License Inspection
- Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open . . .
Capricor Therapeutics (NASDAQ: CAPR) is a biotechnology company dedicated to advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases At the forefront of our innovation is our lead product candidate, Deramiocel, an allogeneic cardiac-derived cell therapy
- Press Releases :: Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
|
|
|